Efficacy and safety of vildagliptin as add-on therapy to metformin in patients with type 2 diabetes
Phase 3
- Conditions
- Type 2 diabetes mellitus
- Registration Number
- JPRN-jRCT2080221679
- Lead Sponsor
- ovartis Pharma K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 136
Inclusion Criteria
Patients with type 2 diabetes inadequately controlled with diet, exercise and oral anti-diabetic therapy
- HbA1c in the range of 7.0-10.0%
- Body mass index in the range 20-35 kg/m2
Exclusion Criteria
- Type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes
- Significant heart diseases
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HbA1c
- Secondary Outcome Measures
Name Time Method HbA1c, Fasting plasma glucose, Safety